For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Takeda to Absorb Nihon Pharmaceutical in October
June 27, 2022
- Ono Chief Pledges to Boost Compliance after Bribery Case
June 24, 2022
- 25 Japan Drug Makers Log Combined 10.7% Growth in FY2021, 12 See Two-Digit Jumps: Tally
June 24, 2022
- JCR Executive Pay Tops 100 Million Yen for First Time in FY2021
June 24, 2022
- Pfizer Curbs Stelues Shipment in Japan on Spike in Demand
June 23, 2022
- EMA Starts Enhertu Review for HER2 Low Breast Cancer
June 23, 2022
- Pfizer Files COVID-19 Booster for Children Ages 5-11 in Japan
June 23, 2022
- Biosimilars Likely to Gain Further Impetus from Govt Push; Forteo/Enbrel Hit 40% Share, Herceptin 50%-Plus
June 22, 2022
- Alinamin Invites New President from Non-Pharma Sector
June 22, 2022
- Tokyo Wholesaler Slapped with 10-Day Biz Suspension over Fake Triazolam API
June 22, 2022
- Taiho Lifts Shipment Control on Abraxane
June 21, 2022
- ASKA Licenses Korean Rights for Birth Control Pill Drospirenone
June 21, 2022
- Astellas Workforce Down by More than 700: Securities Report
June 21, 2022
- PeptiDream Set to Develop Peptide-RI Conjugates for Refractory Cancers, Eyes No. 1 Spot in Radiotherapy
June 20, 2022
- Kyorin Snags Rights to Genetically Modified Adipocytes for Fabry Disease
June 20, 2022
- EMA Starts Review of Aripiprazole 2-Month Injectable: Otsuka/Lundbeck
June 20, 2022
- Kissei-Originated Fibroid Drug Approved in Europe
June 20, 2022
- Samsca Authorized Generic Hits Shelves in Japan
June 20, 2022
- Taisho’s Lusefi OD Film Now Available in Japan
June 20, 2022
- Takeda Founding Family to Vote against Foreign Leadership
June 17, 2022
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…